![9-[(2R,3S,5S)-3-Fluoro-5-(Hydroxymethyl)Oxolan-2-Yl]-3H-Purin-6-One](https://static.cymitquimica.com/products/3D/img/FF98319.png "Click to enlarge")
9-[(2R,3S,5S)-3-Fluoro-5-(Hydroxymethyl)Oxolan-2-Yl]-3H-Purin-6-One
CAS: 117525-25-4
Ref. 3D-FF98319
| Undefined size | To inquire |
Product Information
- 2'-F-dd-Aral
- 6H-Purin-6-one, 9-(2,3-dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)-1,9-dihydro-
- 9-(2,3-dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)-3,9-dihydro-6H-purin-6-one
9-[(2R,3S,5S)-3-Fluoro-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one (FHA) is a prodrug that contains a hydroxymethyl group. FHA can be hydrolyzed by the enzyme aldehyde oxidase to form 9-[(2R,3S,5S)-3-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one (FAU). FAU is more potent than FHA and has been shown to inhibit HIV replication in cell culture. FHA was administered to humans and its pharmacokinetic properties were studied. The plasma concentration of FHA increased with time after administration and reached a maximum level at about 3 hours. The maximum concentration of FAU was found at about 1 hour. The elimination half life of both compounds was approximately 2 hours. The workstation architecture used
Chemical properties
Technical inquiry about: 3D-FF98319 9-[(2R,3S,5S)-3-Fluoro-5-(Hydroxymethyl)Oxolan-2-Yl]-3H-Purin-6-One
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
